Xenoview is a hyperpolarized contrast agent approved by the U.S. Food and Drug Administration (FDA) for use with MRI to evaluate lung ventilation in adults and children ages 12 years and older.

The company said the first patient to receive a Xenoview scan is a 19-year-old male with cystic fibrosis. Xenoview's dose is set through the company's HPX Hyperpolarization System and administered in a single 10- to 15-second breath hold MRI procedure, according to the firm.